End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34 TWD | -1.59% | -6.72% | -9.33% |
Mar. 13 | Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2021 | 110M 3.43M | Sales 2022 | 188M 5.88M | Capitalization | 4.02B 126M |
---|---|---|---|---|---|
Net income 2021 | -47M -1.47M | Net income 2022 | -248M -7.74M | EV / Sales 2021 | 18.4 x |
Net cash position 2021 | 342M 10.67M | Net cash position 2022 | 457M 14.28M | EV / Sales 2022 | 18.9 x |
P/E ratio 2021 |
-49.9
x | P/E ratio 2022 |
-15.7
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 31.48% |
1 day | -1.59% | ||
1 week | -6.72% | ||
Current month | -0.44% | ||
1 month | +2.56% | ||
3 months | -10.76% | ||
6 months | -6.34% | ||
Current year | -9.33% |
Managers | Title | Age | Since |
---|---|---|---|
Che Wei Chang
CEO | Chief Executive Officer | - | 17-06-07 |
Chung Cheng Liu
CHM | Chairman | - | 14-01-01 |
Ching Fen Yang
CTO | Chief Tech/Sci/R&D Officer | - | 14-07-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chung Chi Li
BRD | Director/Board Member | - | 20-06-16 |
Che Wei Chang
CEO | Chief Executive Officer | - | 17-06-07 |
Chung Cheng Liu
CHM | Chairman | - | 14-01-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 34 | -1.59% | 77,261 |
24-05-14 | 34.55 | +0.14% | 50,406 |
24-05-13 | 34.5 | -1.71% | 82,050 |
24-05-10 | 35.1 | -1.68% | 110,207 |
24-05-09 | 35.7 | -2.06% | 79,281 |
End-of-day quote Taipei Exchange, May 14, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-9.33% | 69.61M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- 6564 Stock